ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by Global Alpha Capital Management Ltd.

Global Alpha Capital Management Ltd. raised its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 1.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 536,450 shares of the specialty pharmaceutical company's stock after purchasing an additional 9,500 shares during the quarter. ANI Pharmaceuticals accounts for 2.1% of Global Alpha Capital Management Ltd.'s portfolio, making the stock its 23rd largest holding. Global Alpha Capital Management Ltd. owned approximately 2.55% of ANI Pharmaceuticals worth $32,005,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Millennium Management LLC boosted its holdings in shares of ANI Pharmaceuticals by 1,005.8% in the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company's stock valued at $14,651,000 after buying an additional 209,272 shares during the period. Mizuho Markets Americas LLC bought a new stake in ANI Pharmaceuticals in the third quarter valued at approximately $11,670,000. Assenagon Asset Management S.A. boosted its position in ANI Pharmaceuticals by 149.7% during the third quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company's stock worth $11,107,000 after purchasing an additional 111,613 shares during the period. F M Investments LLC bought a new position in ANI Pharmaceuticals in the 3rd quarter valued at about $3,686,000. Finally, American Century Companies Inc. grew its holdings in ANI Pharmaceuticals by 99.2% in the 2nd quarter. American Century Companies Inc. now owns 99,831 shares of the specialty pharmaceutical company's stock valued at $6,357,000 after buying an additional 49,717 shares in the last quarter. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Trading Down 1.1 %

Shares of NASDAQ:ANIP traded down $0.59 on Wednesday, hitting $55.10. 244,897 shares of the company's stock were exchanged, compared to its average volume of 218,291. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -100.85 and a beta of 0.71. The business's 50 day simple moving average is $58.34 and its two-hundred day simple moving average is $61.11. ANI Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million during the quarter, compared to analysts' expectations of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business's revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.05 EPS. Analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Truist Financial raised their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a report on Tuesday, October 22nd. Piper Sandler began coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an "overweight" rating and a $68.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. StockNews.com cut shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Finally, Raymond James increased their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a report on Wednesday, September 18th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $77.33.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.